|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM267249381 |
| 003 |
DE-627 |
| 005 |
20231224220252.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.10.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0890.xml
|
| 035 |
|
|
|a (DE-627)NLM267249381
|
| 035 |
|
|
|a (NLM)27989895
|
| 035 |
|
|
|a (PII)S1521-6616(16)30533-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Khosravi-Maharlooei, Mohsen
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intraperitoneal injection of IDO-expressing dermal fibroblasts improves the allograft survival
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.06.2017
|
| 500 |
|
|
|a Date Revised 11.06.2018
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme with tolerogenic effects on different immune cells. Our group has previously shown that co-transplantation of IDO-expressing fibroblasts with donor tissues can delay immune rejection by inducing local immunosuppression. In this study, we have employed a systemic approach to improve allograft survival without using any immunosuppressive medication. To achieve this, 10 million lentiviral transduced IDO-expressing donor derived fibroblasts were injected into the peritoneal cavity of allograft recipients. We showed that IDO-fibroblast therapy increases the survival of both islets and skin allografts and decreases the infiltration of immune cells in subcutaneous transplanted skins. Indirect pathway of allo-reactive T cell activation was suppressed more than the direct pathway. Injected IDO-fibroblasts were found in peritoneal cavity and mesenteric lymph nodes of the recipient mice. In conclusion, IDO-expressing fibroblast therapy proved to be a novel approach in improving the allogeneic graft survival
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Allograft survival
|
| 650 |
|
4 |
|a Fibroblast
|
| 650 |
|
4 |
|a Indoleamine 2,3-dioxygenase
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Indoleamine-Pyrrole 2,3,-Dioxygenase
|2 NLM
|
| 700 |
1 |
|
|a Pakyari, MohammadReza
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jalili, Reza B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kilani, Ruhangiz T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ghahary, Aziz
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 174(2017) vom: 14. Jan., Seite 1-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:174
|g year:2017
|g day:14
|g month:01
|g pages:1-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.10.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 174
|j 2017
|b 14
|c 01
|h 1-9
|